Cephalon’s Nuvigil For Jet Lag Is Pulled Off The Runway; Bipolar Indication Remains On The Horizon
This article was originally published in The Pink Sheet Daily
A second “complete response” letter from FDA derails development of the jet lag claim; Cephalon repeatedly has struck out in seeking a new indication to differentiate the wakefulness drug from Provigil.
You may also be interested in...
The specialty pharma has made plenty of acquisitions and is pursuing late-stage options, but the upcoming loss of its lead product to generic competition may not be filled by the risky pipeline.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.